Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera
- PMID: 2184337
- DOI: 10.1007/BF00190145
Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera
Abstract
The prevalence of antibodies against HIV-1 regulatory proteins in sera of HIV-infected patients from different stages of disease was investigated. HIV-1 vif, tat, and nef genes were cloned in procaryotic vectors and were expressed as MS-2 fusion proteins (vif and nef) or as a non-fusion protein (tat). These recombinant proteins were employed in immunoblot experiments. The specificity of the recognition was confirmed by competition experiments and with control sera from HIV-negative patients. Analysis of 136 serum samples revealed a high percentage of antibodies against nef, irrespective of the stage of disease. Antibodies against tat were found less frequently and increased from 16% to 40% with disease progression. Vif antibodies were detected only in a low percentage in early stages of disease, but their prevalence increased to 36% and 72% with progression of disease to AIDS-related complex and AIDS. Our data suggest that the detection of antibodies against nef may represent an additional and useful marker for the diagnosis of HIV infection, whereas the detection of vif antibodies may indicate disease progression.
Similar articles
-
Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes.AIDS. 2000 Jan 7;14(1):1-9. doi: 10.1097/00002030-200001070-00001. AIDS. 2000. PMID: 10714562
-
Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals.J Acquir Immune Defic Syndr (1988). 1991;4(2):165-72. J Acquir Immune Defic Syndr (1988). 1991. PMID: 1898969
-
gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants.J Virol. 1998 May;72(5):4308-19. doi: 10.1128/JVI.72.5.4308-4319.1998. J Virol. 1998. PMID: 9557721 Free PMC article.
-
Role of viral regulatory and accessory proteins in HIV-1 replication.Front Biosci. 2004 Sep 1;9:2388-413. doi: 10.2741/1403. Front Biosci. 2004. PMID: 15353294 Review.
-
HIV accessory proteins: emerging therapeutic targets.Mol Med. 1995 Jul;1(5):479-85. Mol Med. 1995. PMID: 8529114 Free PMC article. Review. No abstract available.
Cited by
-
In vitro cleavage of HIV-1 vif RNA by a synthetic ribozyme.Virus Genes. 1991 Jan;5(1):17-23. doi: 10.1007/BF00571727. Virus Genes. 1991. PMID: 2017874
-
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7941-5. doi: 10.1073/pnas.90.17.7941. Proc Natl Acad Sci U S A. 1993. PMID: 7690138 Free PMC article.
-
Characterization of Tat antibody responses in Chinese individuals infected with HIV-1.PLoS One. 2013;8(4):e60825. doi: 10.1371/journal.pone.0060825. Epub 2013 Apr 2. PLoS One. 2013. PMID: 23565278 Free PMC article.
-
Serological markers as prognostic criteria for the course of HIV infection.Infection. 1991;19 Suppl 2:S89-92. doi: 10.1007/BF01644474. Infection. 1991. PMID: 1901833
-
Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.J Virol. 2004 Sep;78(17):9174-89. doi: 10.1128/JVI.78.17.9174-9189.2004. J Virol. 2004. PMID: 15308713 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical